Arkan Zwick Q&A, Part 1: Choosing An EU Notified Body For Drug/Device Combinations In A Rapidly Changing Environment
Executive Summary
Selecting a notified body that has capacity, expertise and staying power is a challenge in itself. But when it comes to selecting a good one for drug/device combinations products, how should companies proceed? Croma Pharma executive Arkan Zwick offers his insight in this first part of a two-part Q&A. Check out the second part here.
You may also be interested in...
EU Combo-Product Review In A Rapidly Changing Environment
Croma Pharma executive Arkan Zwick talks about the challenges of getting the drug element of a device-type drug/device combination product reviewed in the EU and how companies should proceed in selecting a notified body to review combinations.
Arkan Zwick Q&A, Part 2: EU Combo-Product Review Challenges
In the second half of a Q&A with Medtech Insight, Croma Pharma executive Arkan Zwick talks about the challenges of getting the drug element of a device-type combination product reviewed in the EU and what combo-product firms have to look out for under the oncoming Medical Devices Regulation. Read the first part of the conversation here.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.